Correlation Between Kura Oncology and Inhibrx
Can any of the company-specific risk be diversified away by investing in both Kura Oncology and Inhibrx at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Kura Oncology and Inhibrx into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Kura Oncology and Inhibrx, you can compare the effects of market volatilities on Kura Oncology and Inhibrx and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Kura Oncology with a short position of Inhibrx. Check out your portfolio center. Please also check ongoing floating volatility patterns of Kura Oncology and Inhibrx.
Diversification Opportunities for Kura Oncology and Inhibrx
0.52 | Correlation Coefficient |
Very weak diversification
The 3 months correlation between Kura and Inhibrx is 0.52. Overlapping area represents the amount of risk that can be diversified away by holding Kura Oncology and Inhibrx in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Inhibrx and Kura Oncology is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Kura Oncology are associated (or correlated) with Inhibrx. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Inhibrx has no effect on the direction of Kura Oncology i.e., Kura Oncology and Inhibrx go up and down completely randomly.
Pair Corralation between Kura Oncology and Inhibrx
Given the investment horizon of 90 days Kura Oncology is expected to under-perform the Inhibrx. In addition to that, Kura Oncology is 1.22 times more volatile than Inhibrx. It trades about -0.12 of its total potential returns per unit of risk. Inhibrx is currently generating about 0.01 per unit of volatility. If you would invest 1,514 in Inhibrx on September 19, 2024 and sell it today you would lose (19.00) from holding Inhibrx or give up 1.25% of portfolio value over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Together |
Strength | Weak |
Accuracy | 99.21% |
Values | Daily Returns |
Kura Oncology vs. Inhibrx
Performance |
Timeline |
Kura Oncology |
Inhibrx |
Kura Oncology and Inhibrx Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Kura Oncology and Inhibrx
The main advantage of trading using opposite Kura Oncology and Inhibrx positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Kura Oncology position performs unexpectedly, Inhibrx can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Inhibrx will offset losses from the drop in Inhibrx's long position.Kura Oncology vs. Protagonist Therapeutics | Kura Oncology vs. Merus BV | Kura Oncology vs. Replimune Group | Kura Oncology vs. Kalvista Pharmaceuticals |
Inhibrx vs. Crinetics Pharmaceuticals | Inhibrx vs. Merus BV | Inhibrx vs. Lyell Immunopharma | Inhibrx vs. Kronos Bio |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Other Complementary Tools
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
CEOs Directory Screen CEOs from public companies around the world | |
FinTech Suite Use AI to screen and filter profitable investment opportunities |